Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

被引：6

作者：

Pemmaraju, Naveen ^{[1
]}

Harrison, Claire ^{[2
]}

Gupta, Vikas ^{[3
]}

Verstovsek, Srdan ^{[1
]}

Scott, Bart ^{[4
]}

Oh, Stephen T. ^{[5
]}

Palandri, Francesca ^{[6
]}

Al-Ali, Haifa Kathrin ^{[7
]}

Sobas, Marta ^{[8
]}

McMullin, Mary Frances ^{[9
]}

Mesa, Ruben ^{[10
]}

Buckley, Sarah ^{[11
]}

Roman-Torres, Karisse ^{[11
]}

Vannucchi, Alessandro ^{[12
]}

Yacoub, Abdulraheem ^{[13
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Guys & St Thomas NHS Fdn Trust, London, England

[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] IRCCS Azienda Osped Univ Bologna, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[7] Univ Hosp Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[8] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transpl, Wroclaw, Poland

[9] Queens Univ Belfast, Belfast, North Ireland

[10] UT Hlth San Antonio MD Anderson Canc Ctr, San Antonio, TX USA

[11] CTI Biopharm, Seattle, WA USA

[12] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[13] Univ Kansas Canc Ctr, Westwood, KS USA

来源：

EJHAEM | 2022年 / 3卷 / 04期

关键词：

myelofibrosis; myeloproliferative neoplasms; pacritinib; safety;

D O I：

10.1002/jha2.591

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk-adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.

引用

页码：1346 / 1351

页数：6

共 50 条

[1] The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2V617F Allele Burden
Verstovsek, Srdan
Scott, Bart L.
Taylor, Jason A.
Mascarenhas, John
BLOOD, 2019, 134
[2] Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).
Pemmaraju, Naveen
Scott, Bart L.
Savona, Michael R.
Oh, Stephen T.
Harrison, Claire
Vannucchi, Alessandro M.
Palandri, Francesca
Al-Ali, Haifa Kathrin
Sobas, Marta
Mary, Frances McMullin
Gupta, Vikas
Mesa, Ruben A.
Buckley, Sarah
Roman-Torres, Karisse
Verstovsek, Srdan
Yacoub, Abdulraheem
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
Vaddi, Kris
Sarlis, Nicholas J.
Gupta, Vikas
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
[4] A closer look at pacritinib: a JAK2/FLT3 inhibitor for the treatment of myelofibrosis
Padrnos, Leslie
Mesa, Ruben A.
EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (07): : 725 - 733
[5] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S.
Seymour, John F.
Roberts, Andrew W.
Wadleigh, Martha
To, L. Bik
Scherber, Robyn
Turba, Elyce
Dorr, Andrew
Zhu, Joy
Wang, Lixia
Granston, Tanya
Campbell, Mary S.
Mesa, Ruben A.
BLOOD, 2015, 125 (17) : 2649 - 2655
[6] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A.
Laborde, R. R.
Lasho, T. L.
Finke, C.
Begna, K.
Al-Kali, A.
Hogan, W. J.
Litzow, M. R.
Leontovich, A.
Kowalski, M.
Tefferi, A.
LEUKEMIA, 2013, 27 (06) : 1322 - 1327
[7] Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A Pardanani
R R Laborde
T L Lasho
C Finke
K Begna
A Al-Kali
W J Hogan
M R Litzow
A Leontovich
M Kowalski
A Tefferi
Leukemia, 2013, 27 : 1322 - 1327
[8] Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
Lancman, Guido
Mascarenhas, John
EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (01) : 23 - 28
[9] PACRITINIB Inhibitor of Tyrosine-Protein Kinase JAK2 Inhibitor of FLT-3 Treatment of Myelofibrosis
Verstovsek, S.
Machida, C.
Dean, J. P.
Myint, H.
DRUGS OF THE FUTURE, 2013, 38 (06) : 375 - 386
[10] Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Verstovsek, Srdan
Kantarjian, Hagop
Mesa, Ruben A.
Pardanani, Animesh D.
Cortes-Franco, Jorge
Thomas, Deborah A.
Estrov, Zeev
Fridman, Jordan S.
Bradley, Edward C.
Erickson-Viitanen, Susan
Vaddi, Kris
Levy, Richard
Tefferi, Ayalew
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (12): : 1117 - 1127

← 1 2 3 4 5 →